Kissei Pharmaceutical Co., Ltd. (TYO:4547)
Japan · Delayed Price · Currency is JPY | Market Cap | 181.15B +17.9% |
| Revenue (ttm) | 95.29B +14.3% |
| Net Income | 14.14B +21.2% |
| EPS | 337.35 +27.2% |
| Shares Out | 41.45M |
| PE Ratio | 12.95 |
| Forward PE | 15.16 |
| Dividend | 120.00 (2.75%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 134,700 |
| Average Volume | 82,240 |
| Open | 4,360.00 |
| Previous Close | 4,360.00 |
| Day's Range | 4,320.00 - 4,405.00 |
| 52-Week Range | 3,750.00 - 5,040.00 |
| Beta | -0.15 |
| RSI | 34.00 |
| Earnings Date | May 11, 2026 |
About Kissei Pharmaceutical
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of rena... [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2025, Kissei Pharmaceutical's revenue was 88.33 billion, an increase of 16.87% compared to the previous year's 75.58 billion. Earnings were 11.96 billion, an increase of 7.18%.
Financial StatementsNews
Kissei Pharmaceutical initiated with a Neutral at UBS
UBS initiated coverage of Kissei Pharmaceutical (KSPHF) with a Neutral rating and 4,900 yen price target The firm says the company’s business stability is priced into the shares with limited
Kissei Pharmaceutical downgraded to Hold from Buy at Jefferies
Jefferies analyst Stephen Barker downgraded Kissei Pharmaceutical to Hold from Buy with a price target of 3,400 yen, up from 3,300 yen. The analyst cites valuation for the downgrade following